| Craig L Mcclure, MD | |
|
1501 N Campbell Ave, Tucson, AZ 85724-0001 | |
| (520) 694-8888 | |
| (520) 694-1677 |
| Full Name | Craig L Mcclure |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Location | 1501 N Campbell Ave, Tucson, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124119037 | NPI | - | NPPES |
| 207375 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 9490 (Arizona) | Primary |
| Entity Name | Banner -- University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508809427 PECOS PAC ID: 7719899871 Enrollment ID: O20031105000694 |
News Archive
Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer Dr. Chris Yu announced that Venture Capital (VC) Firm, Shanghai Zhangjiang Science &Technology Investment Corporation (ZJSTIC), as well as private investors related to the insurance industry, have again invested over $2 Million to support Anpac's "Cancer Differentiation Analysis" (CDA) technology.
Determining the mechanisms that shape biological membranes has long been a tricky business. Like a factory assembly line, eukaryotic cells are organized into membrane-bound, functional compartments called organelles.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
Meda has signed an agreement to acquire MidNite, an OTC sleep-aid product. MidNite is well established in the U.S. and holds a market leading position within a growing category. Annualized revenues for MidNite are approximately 100 MSEK.
Health Discovery Corporation is pleased to announce numerous additional issued patents and Notices of Allowance since its last press release describing its intellectual property portfolio. The Company now has a total of 37 issued patents, 4 Notices of Allowance and 30 pending patent applications.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Craig L Mcclure, MD 2701 E Elvira Rd, Tucson, AZ 85706-7124 Ph: (520) 874-3500 | Craig L Mcclure, MD 1501 N Campbell Ave, Tucson, AZ 85724-0001 Ph: (520) 694-8888 |
News Archive
Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer Dr. Chris Yu announced that Venture Capital (VC) Firm, Shanghai Zhangjiang Science &Technology Investment Corporation (ZJSTIC), as well as private investors related to the insurance industry, have again invested over $2 Million to support Anpac's "Cancer Differentiation Analysis" (CDA) technology.
Determining the mechanisms that shape biological membranes has long been a tricky business. Like a factory assembly line, eukaryotic cells are organized into membrane-bound, functional compartments called organelles.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
Meda has signed an agreement to acquire MidNite, an OTC sleep-aid product. MidNite is well established in the U.S. and holds a market leading position within a growing category. Annualized revenues for MidNite are approximately 100 MSEK.
Health Discovery Corporation is pleased to announce numerous additional issued patents and Notices of Allowance since its last press release describing its intellectual property portfolio. The Company now has a total of 37 issued patents, 4 Notices of Allowance and 30 pending patent applications.
› Verified 6 days ago
Emma Rose Holbrook, Hospitalist Medicare: Medicare Enrolled Practice Location: 1625 N Campbell Ave, Tucson, AZ 85719 Phone: 520-694-0111 | |
Dr. Raquel Maria Bravo-clouzet, MD, MPH Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 5301 E Grant Rd, Tucson, AZ 85712 Phone: 520-324-2594 | |
Carly Lasure, PA Hospitalist Medicare: Medicare Enrolled Practice Location: 350 N Wilmot Rd, Tucson, AZ 85711 Phone: 520-873-3000 | |
Girish Jagdish Karamchandani, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 4821 N Stone Ave, Tucson, AZ 85704 Phone: 520-314-3300 Fax: 520-293-1597 | |
Dr. Rachel Lea Camp, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 101 W Irvington Rd, Tucson, AZ 85714 Phone: 520-670-3909 | |
Paul R Gordon, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 707 N Alvernon Way, Suite 101, Tucson, AZ 85711 Phone: 520-694-1611 Fax: 520-694-1677 |